A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer (NCT07512076)

🧪 Interventions in This Study

• Enzalutamide Dose Escalation (DRUG)
• Standard of Care (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Sunnybrook Health Sciences Centre — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (416) 480-4617

Email: daniel.khalaf@sunnybrook.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer Patients

• Expanding Genetic Access for Prostate Cancer Survivors — Washington D.C., District of Columbia
• Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC — Madison, Wisconsin
• Radiation Therapy Approaches for People With Prostate Cancer — Basking Ridge, New Jersey

Explore by condition: All Prostate Cancer Patients clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.